A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In that trial, improvement in pruritus and beneficial effects on markers of fibrosis were also observed.
“Furthermore, improvement in pruritus and beneficial effects on markers of fibrosis were also observed.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [94]
In a multicenter trial of 100 inadequate UDCA responders, UDCA/bezafibrate for 2 years led to 67% normalizing ALP and 30% normalizing all liver tests compared with 0% with placebo.
“Patients on combination UDCA/ bezafibrate had substantial improvement in liver chemistries, with 67% normalizing ALP and 30% normalizing all liver tests compared with 0% treated with placebo.(94)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [94]
Cited by
Sorted by citations
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · see citing works
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253 · see citing works
Reig, A., Sesé, P., & Parés, A. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.287 · Cited by 115 · see citing works
Treatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9 · see citing works
- Authors
- Corpechot, C., Chazouillères, O., Rousseau, A., Guyader, D., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., Abergel, A., Debette-Gratien, M., Larrey, D., Roux, O., Bronowicki, J.-P., Boursier, J., de Ledhingen, V., Heurgue-Berlot, A., Nguyen-Khac, E., Zoulim, F., Ollivier-Hourmand, I., Zarski, J.-P., Nkontchou, G., Gaouar, F., Simon, T., & Poupon, R.
- Affiliations
- Hôpital Saint-Antoine (FR)
- Foie, Métabolisme, Cancer (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Centre hospitalier universitaire d'Orléans (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Institut d'Astrophysique Spatiale (FR)
- Hôpital Saint Eloi (FR)
- Hôpital Beaujon (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017
- Volume
- 66
- Issue
- 1
- Pages
- S89
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2613681362
- Cited by
- 45
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 3 · 2020: 3 · 2019: 6 · 2018: 20 · 2017: 10
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- bezafibrate, primary biliary cirrhosis, ursodeoxycholic acid, fibrate therapy, bile acid synthesis inhibition, treatment efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
